Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial
Journal
Vaccine
Journal Volume
35
Journal Issue
33
Pages
4099-4104
Date Issued
2017
Author(s)
Lee W.-S.
Wang N.-C.
Ou T.-Y.
Chen F.-L.
Lin T.-Y.
Abstract
Background We conducted a phase I/II clinical trial to evaluate the safety and immunogenicity of a Madin-Darby canine kidney (MDCK) cell-grown inactivated H7N9 influenza vaccine for pandemic preparedness purposes. Methods Between April 7, 2015 and May 27, 2016, healthy adults aged 20–60 years were enrolled sequentially in phase I (n = 40) and phase II (n = 160) from three hospitals in Taiwan and randomized to receive 2 doses of whole-virus H7N9 vaccine (15 or 30 μg hemagglutinin antigen (HA) with or without an aluminum hydroxide adjuvant) at 21-day intervals. Safety up to 180 days and changes in hemagglutinin inhibition (HI) titers at 21 days after each vaccination were determined. Results Of the 200 randomized subjects, 193 (96.5%) received 2 doses of the study vaccine and were included in the intention-to-treat analysis for safety, and 190 (95%) were included in the per-protocol analysis for immunogenicity. Most adverse events were mild and transient; no death or vaccine-related serious adverse events were reported. Overall, higher immune responses were observed in the groups administered with 30 μg HA formulation than in the other two groups administered with 15 μg HA formulation. The highest immune response was observed in subjects who received 2 doses of the adjuvanted vaccine containing 30 μg HA with HI titer, seroprotection rate, seroconversion rate, and seroconversion factor of 36.2, 64.6%, 64.6% and 5.7, respectively. Conclusions Our study demonstrated that the H7N9 influenza vaccine containing 30 ?g HA with aluminum hydroxide adjuvant was immunogenic and safe in adults aged 20–60 years. CLINICALTRIALS.GOV identifier: NCT02436928. ? 2017 Elsevier Ltd
SDGs
Other Subjects
aluminum hydroxide; antigen; hemagglutinin antigen; influenza vaccine; unclassified drug; aluminum hydroxide; immunological adjuvant; inactivated vaccine; influenza vaccine; virus antibody; adult; arthralgia; Article; cell culture; controlled study; drug formulation; drug safety; erythema; fatigue; female; fever; headache; hemagglutination inhibition test; hematoma; human; immune response; immunogenicity; influenza A (H7N9); Influenza A virus (H7N9); intention to treat analysis; male; MDCK cell line; myalgia; normal human; pain; phase 1 clinical trial; phase 2 clinical trial; priority journal; randomized controlled trial; seroconversion; shivering; skin induration; swelling; adverse drug reaction; animal; blood; cell culture technique; clinical trial; dog; immunization; immunology; influenza; middle aged; pathology; pharmaceutics; prospective study; Taiwan; virology; young adult; Adjuvants, Immunologic; Adult; Aluminum Hydroxide; Animals; Antibodies, Viral; Cell Culture Techniques; Dogs; Drug-Related Side Effects and Adverse Reactions; Female; Healthy Volunteers; Hemagglutination Inhibition Tests; Humans; Immunization Schedule; Influenza A Virus, H7N9 Subtype; Influenza Vaccines; Influenza, Human; Madin Darby Canine Kidney Cells; Male; Middle Aged; Prospective Studies; Taiwan; Technology, Pharmaceutical; Vaccines, Inactivated; Young Adult
Publisher
Elsevier Ltd
Type
journal article